UNSPSC 51142527: Etilevodopa

This classification denotes an antiparkinsonian agent with the molecular formula C11H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 895X917GYE, chemically known as (-)-3,4-dihydroxy-l-phenylalanine, ethyl ester but generally known as etilevodopa, which bears US NIH Compound Identifier 170345. European Medicines Agency schedules Etilevodopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02042MIG.

UNSPSC 51142527 Etilevodopa is a Commodity code. Recent state and local procurement activity under this code shows a fundamental mismatch: the single recent solicitation tags naloxone and drug deactivation systems, which fall outside the scope of etilevodopa (a levodopa-carbidopa combination medication used to treat Parkinson's disease). The solicitation appears to reflect a coding error in the issuing jurisdiction's procurement system rather than actual demand for etilevodopa itself. State and local governments do procure pharmaceutical products including treatments for neurological conditions through health departments, county health systems, and emergency services agencies, but this particular opportunity does not represent genuine activity under the etilevodopa code.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The response deadline was July 26, 2023 (a date that predates the posting, suggesting data quality issues in the source record). The procurement included standard state and local requirements—E-Verify compliance, drug-free workplace certification, commercial general liability and workers' compensation insurance, and a three-month probationary termination clause—and was potentially funded through FEMA with corresponding federal compliance obligations. No set-aside designations for disadvantaged enterprises were specified. The code shows no other recent state and local opportunities and limited relevance to actual etilevodopa procurement.